Harlow, United Kingdom

Gerard Martin Paul Giblin

This inventor holds 16 USPTO granted patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Glaxo Group Limited, Smithkline Beecham Corporation. Active years: 2005-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gerard Martin Paul Giblin. Retrieved from https://idiyas.com/inventor/gerard-martin-paul-giblin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 6.3

 

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 43(Granted Patents)


Location History:

  • Hertfordshire, GB (2005)
  • The Frythe, GB (2007)
  • Welwyn, GB (2005 - 2010)
  • Harlow, GB (2008 - 2012)

Company Filing History:


Years Active: 2005-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Sphingosine 1-Phosphate Agonists
Benzoisoindole Derivatives
EP4 Receptor Agonists
Pyridine Compounds
Naphthalene Derivatives
Pyrimidine Derivatives
CB2 Modulators
Indole Derivatives
Pain Treatment
Neuropathic Pain
Colon Cancer
16 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Gerard Martin Paul Giblin

Introduction

Gerard Martin Paul Giblin is a notable inventor based in Harlow, GB. He has made significant contributions to the field of pharmacology, holding a total of 16 patents. His work primarily focuses on developing compounds with therapeutic applications.

Latest Patents

One of Giblin's latest patents involves oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists. This invention provides compounds of a specific formula, along with their salts, that exhibit pharmacological activity. The patent details processes for preparing these compounds, pharmaceutical compositions containing them, and their applications in treating various disorders mediated by S1P1 receptors.

Career Highlights

Throughout his career, Giblin has worked with prominent companies in the pharmaceutical industry, including Glaxo Group Limited and SmithKline Beecham Corporation. His expertise in drug development has positioned him as a valuable asset in the field.

Collaborations

Giblin has collaborated with notable professionals such as Neil Derek Miller and Mark Patrick Healy. These partnerships have likely contributed to the advancement of his innovative projects.

Conclusion

Gerard Martin Paul Giblin's work exemplifies the impact of innovation in pharmacology. His patents and collaborations reflect a commitment to advancing medical science through inventive solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…